## Fiscal Year 2016 Tuberous Sclerosis Complex Research Program (TSCRP)
### Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Exploration - Hypothesis Development Award** | Investigators at all academic levels (or equivalent), including postdoctoral fellows | • Supports the initial exploration of innovative, high-risk, high-gain concepts in TSC research field.  
• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.  
• Preliminary data not required.  
• Clinical trials not allowed. | • The maximum period of performance is 2 years.  
• The maximum allowable funding for the entire period of performance is **$200,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent): July 1, 2016 5:00 p.m. Eastern time (ET)  
Application: July 18, 2016 11:59 p.m. ET |
| **Idea Development Award**                | Established Investigators: Independent investigator at or above the level of Assistant Professor (or equivalent);  
Or New Investigators: Independent investigator at or below the level of Assistant Professor (or equivalent); or Established investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC | • Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.  
• Preliminary data is expected.  
• New Investigator Option supports applicants who are early in their faculty appointments or in the process of developing independent research careers.  
o Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed separately.  
• Clinical trials not allowed. | • The maximum period of performance is 3 years.  
• The maximum allowable funding for the entire period of performance is **$450,000** in direct costs  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent): July 1, 2016 5:00 p.m. ET  
Application: July 18, 2016 11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Pilot Clinical Trial Award      | Investigators at or above the level of Assistant Professor (or equivalent)   | • Supports exploratory studies with limited human exposure that produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action.  
• Aims at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes.  
• Scientific rationale and preliminary data are required.  
• Preclinical studies will not be supported. | • The maximum period of performance is 2 years.  
• The maximum allowable funding for the entire period of performance is **$300,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 1, 2016  
5:00 p.m. ET  
Application:  
July 18, 2016  
11:59 p.m. ET |
| Postdoctoral Development Award  | PI: Postdoctoral fellow with a total of 3 years or less of postdoctoral research experience working in the Mentor’s laboratory  
Mentor: Experienced TSC researcher at or above the level of an Assistant Professor (or equivalent) | The PI and the Mentor must be at the same organization.  
• Supports recent doctoral or medical graduates to conduct impactful research with the mentorship of an experienced TSC researcher.  
• Encourages junior investigators to develop and investigate a TSC research project and further their intellectual development as a TSC researcher of the future.  
• Preliminary data is not required.  
• Clinical trials not allowed. | • The maximum period of performance is 2 years.  
• The maximum allowable funding for the entire period of performance is **$150,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 1, 2016  
5:00 p.m. ET  
Application:  
July 18, 2016  
11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synergistic Idea Development Award:</td>
<td></td>
<td>• Supports new or existing partnerships between two or three Principal Investigators, who should utilize their complementary and synergistic perspectives to significantly accelerate advances in TSC research.</td>
<td>The maximum period of performance is 3 years</td>
<td>Pre-application (Letter of Intent):</td>
</tr>
<tr>
<td></td>
<td>Each PI must be at or above the level of Assistant Professor (or equivalent).</td>
<td>• Must clearly define the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single PI.</td>
<td>The maximum allowable funding for the entire period of performance is $750,000 in direct costs.</td>
<td>July 1, 2016 5:00 p.m. ET</td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number:</td>
<td></td>
<td>• One PI will be identified as the Initiating PI; the other PI(s) as a Partnering PI(s); each PI will receive his/her own award.</td>
<td>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: July 18, 2016 11:59 p.m. ET</td>
</tr>
<tr>
<td>W81XWH-16-TSCRP-SIDA</td>
<td></td>
<td>• Preliminary data is expected.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>